Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Canagliflozin slows the progression of chronic kidney disease in patients with type 2 diabetes and induces a reversible acute drop in estimated glomerular filtration rate (eGFR), believed to be a hemodynamic effect. Predictors of the initial drop and its association with long-term eGFR trajectories...

Celý popis

Podrobná bibliografie

Vydáno v:	Kidney international Ročník 99; číslo 4; s. 999
Hlavní autoři:	Oshima, Megumi, Jardine, Meg J, Agarwal, Rajiv, Bakris, George, Cannon, Christopher P, Charytan, David M, de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Levin, Adeera, Lim, Soo Kun, Mahaffey, Kenneth W, Neal, Bruce, Pollock, Carol, Rosenthal, Norman, Wheeler, David C, Zhang, Hong, Zinman, Bernard, Perkovic, Vlado, Heerspink, Hiddo J L
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.04.2021
Témata:	Canagliflozin - adverse effects Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Glomerular Filtration Rate Humans Renal Insufficiency, Chronic - diagnosis Sodium-Glucose Transporter 2 Inhibitors - adverse effects chronic kidney disease type 2 diabetes SGLT2 inhibitor canagliflozin
ISSN:	1523-1755, 1523-1755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!